|
| 1 |
|
Conditions listed in this trial |
|
|
Breast Cancer |
|
|
Leukemia |
|
|
Lymphoma |
|
|
Neuroblastoma |
|
|
Ovarian Cancer |
|
|
Sarcoma |
|
| 2 |
|
Additional conditions recognized in this trial |
|
|
Breast Neoplasms |
|
|
Lymphoma, Non-Hodgkin |
|
|
Multiple Myeloma |
|
|
Neoplasms, Plasma Cell |
|
|
Ovarian Neoplasms |
|
| 3 |
|
More general conditions related to this trial |
|
|
Adnexal Diseases |
|
|
Blood Protein Disorders |
|
|
Breast Diseases |
|
|
Cardiovascular Diseases |
|
|
Endocrine Gland Neoplasms |
|
|
Endocrine System Diseases |
|
|
Genital Diseases, Female |
|
|
Genital Neoplasms, Female |
|
|
Gonadal Disorders |
|
|
Hematologic Diseases |
|
|
Hemorrhagic Disorders |
|
|
Hemostatic Disorders |
|
|
Immune System Diseases |
|
|
Immunoproliferative Disorders |
|
|
Lymphatic Diseases |
|
|
Lymphoproliferative Disorders |
|
|
Neoplasms |
|
|
Neoplasms by Histologic Type |
|
|
Neoplasms by Site |
|
|
Neoplasms, Connective and Soft Tissue |
|
|
Neoplasms, Germ Cell and Embryonal |
|
|
Neoplasms, Glandular and Epithelial |
|
|
Neoplasms, Nerve Tissue |
|
|
Neoplasms, Neuroepithelial |
|
|
Neuroectodermal Tumors |
|
|
Neuroectodermal Tumors, Primitive |
|
|
Neuroectodermal Tumors, Primitive, Peripheral |
|
|
Ovarian Diseases |
|
|
Paraproteinemias |
|
|
Skin Diseases |
|
|
Urogenital Neoplasms |
|
|
Vascular Diseases |
|
| 4 |
|
Interventions listed in this trial |
|
|
amifostine trihydrate |
|
|
cyclophosphamide |
|
|
filgrastim |
|
|
melphalan |
|
| 5 |
|
Additional drug interventions recognized in this trial |
|
|
Amifostine |
|
| 6 |
|
More general drug interventions related to this trial |
|
|
Alkylating Agents |
|
|
Antineoplastic Agents |
|
|
Antineoplastic Agents, Alkylating |
|
|
Antirheumatic Agents |
|
|
Immunologic Factors |
|
|
Immunosuppressive Agents |
|
|
Molecular Mechanisms of Pharmacological Action |
|
|
Myeloablative Agonists |
|
|
Pharmacologic Actions |
|
|
Physiological Effects of Drugs |
|
|
Protective Agents |
|
|
Radiation-Protective Agents |
|
|
Therapeutic Uses |
|
| 7 |
|
Sponsors listed in this trial |
|
|
Lucille P. Markey Cancer Center at University of Kentucky |
